Vertex sold royalties to outlast the 2008 crunch and its CF bet made it a giant

Through the 2008 financial crisis, Vertex Pharmaceuticals was a pure research company: total revenues of $101.9m in 2009, all of it collaboration and royalty income, against a net loss of $642.2m. Its telaprevir hepatitis-C drug was in phase 3 and its cystic fibrosis compound VX-770 was in mid-stage trials, but neither was approved. The credit crunch closed the equity and debt windows a clinical-stage biotech normally leans on, and Vertex had never sold a product.

Management chose to fund the pipeline by selling pieces of its own future. In May 2008 it sold its rights to future GlaxoSmithKline royalties on the HIV drugs Lexiva/Telzir for a one-time $160m. In the third quarter of 2009 it issued a $155m note secured by the first $155m of potential Janssen milestones on telaprevir and sold the remaining $95m outright. A July 2009 amendment with Mitsubishi Tanabe brought another $105m. In all, Vertex raised roughly $1.9bn in the three years to December 2009, ending that year with $1.28bn of cash.

The bet paid on schedule. Telaprevir (Incivek) was approved and launched in the US in May 2011 and ivacaftor (Kalydeco) was approved by the FDA in the first quarter of 2012 — the first drug to treat the underlying cause of cystic fibrosis, which the FDA called an example of personalized medicine. Total revenues went from $143.4m in 2010 to $1.5bn in 2012, with Incivek contributing $1.2bn and Kalydeco $171.6m in 2012, and Vertex booked its first net income in 2011: $29.6m.

Revenue rose from $143.4m in 2010 to $1.5bn in 2012, first profit came in 2011 ($29.6m), and product revenue reached $7.6bn by 2021.

The science was worth funding: telaprevir's phase 3 data were strong and VX-770 was the first CFTR potentiator showing real effect, so the assets had buyers even in a crisis.

Management priced its own future rather than dilute equity at the bottom — selling discounted milestones and royalties raised hundreds of millions without giving up the pipeline.

Focus made the sales clean: Vertex sold non-core HIV royalties while keeping 100% of telaprevir in North America and the CF program worldwide, so the money strengthened rather than split the bet.

Both funded programs reached approval, turning a defensive financing round into two commercial franchises instead of one.

When capital markets close, a company that knows which asset carries the future can sell everything else — even its own royalties — to keep the bet alive. A priced pipeline becomes fuel.

Incivek's US sales peaked in late 2011 and then declined as competitors developed better hepatitis-C regimens, but the crisis-era choice to also fund cystic fibrosis proved decisive. Kalydeco became the platform for a CF franchise — Orkambi and Symdeko followed, and Trikafta, approved in the US in 2019, treats most of the roughly 83,000 CF patients in North America, Europe and Australia. Vertex's product revenue reached $7.57bn in 2021, with $7.5bn of cash on hand — a company that in 2009 had no products at all.